Literature DB >> 4714848

"On-off" phenomena related to high plasma levodopa.

L E Claveria, D B Calne, J G Allen.   

Abstract

The neurological deficit and plasma concentrations of levodopa have been studied in a Parkinsonian patient experiencing "on-off" phenomena. Blind evaluations of transient attacks of dysphonia revealed an association between episodes of neurological deterioration and exceptionally high plasma concentrations of levodopa shortly after ingestion. These results indicate that "on-off" phenomena can be toxic reactions to levodopa rather than deteriorations due to inadequate intake or absorption of the drug. Management of patients subject to such attacks should be aimed at minimizing fluctuations in the serum level of the drug.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4714848      PMCID: PMC1589642          DOI: 10.1136/bmj.2.5867.641

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  4 in total

1.  Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase.

Authors:  J L Reid; D B Calne; S D Vakil; J G Allen; C A Davies
Journal:  J Neurol Sci       Date:  1972-09       Impact factor: 3.181

2.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

3.  Treatment of Parkinson's disease with levodopa and Ro 4-4602.

Authors:  A Barbeau; L Gillo-Joffroy; H Mars
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

4.  Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa.

Authors:  D B Calne; J L Reid; S D Vakil; S Rao; A Petrie; C A Pallis; J Gawler; P K Thomas; A Hilson
Journal:  Br Med J       Date:  1971-09-25
  4 in total
  6 in total

1.  Bromocriptine and dopamine receptor stimulation.

Authors:  A G Debono; C D Marsden; P Asselman; J D Parkes
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

3.  The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism.

Authors:  S Bergmann; G Curzon; J Friedel; R B Godwin-Austen; C D Marsden; J D Parkes
Journal:  Br J Clin Pharmacol       Date:  1974-10       Impact factor: 4.335

Review 4.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

5.  Treatment of Parkinson's disease: problems with a progressing disease.

Authors:  U K Rinne
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

6.  Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.

Authors:  L Rivera-Calimlim
Journal:  Br J Pharmacol       Date:  1974-02       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.